Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel synthetic, allergen derived peptide desensitizing vaccine currently being developed for the treatment of cat allergy. At present, the efficacy of immunotherapy (peptide or otherwise) can only be established at the conclusion of therapy. The aim of this study is to identify changes in potential biomarkers after peptide immunotherapy that may be subsequently developed as biomarkers that equate with clinical efficacy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Intradermal injection 1 x 4 administrations 4 weeks apart.
Kingston General Hospital
Kingston, Ontario, Canada
Identification of potential plasma biomarkers of response to peptide immunotherapy
Blood samples derived from the study will be submitted for proteomics analyses aimed at the identification of one or more plasma proteins whose concentration over the course of the study varies in relation to the treatment administered. The outcome will be determined on the basis of measurements from samples collected over a period commencing prior to treatment and ending 6 months following treatment.
Time frame: 6 months following last treatment
Symptom scores for ocular and nasal symptoms
Time frame: 4 weeks following treatment
Interleukin production and eosinophil level changes
Time frame: 4 weeks following treatment
Functional genomic changes
Time frame: 4 weeks following treatment
Changes in urine metabolomic profiles
Time frame: 4 weeks following treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.